Plant Name: Anisodus tanguticus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CHRM3; CHRM5; CHRM1; CHRM2; | |
| CTDSP1; TDP1; BLM; HSD17B1; AKR1B1; HSD17B2; NOX4; ALOX15; POLB; | |
| DAPK1; FLT3; | |
| CA2; CA1; CA12; CA9; CA14; CA7; CA3; CA5B; CA5A; CA4; CA6; | |
| AR; | |
| ESRRA; | |
| ALOX5; TYR; XDH; | |
| CASP1; CASP7; | |
| AHR; HIF1A; TP53; | |
| ABCG2; ABCC1; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Small molecule receptor (family A GPCR) | CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 | CHEMBL245 |
| Small molecule receptor (family A GPCR) | CHRM5 | Muscarinic acetylcholine receptor M5 | P08912 | CHEMBL2035 |
| Small molecule receptor (family A GPCR) | CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 | CHEMBL216 |
| Small molecule receptor (family A GPCR) | CHRM2 | Muscarinic acetylcholine receptor M2 | P08172 | CHEMBL211 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.974E-12 | 1.183E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.363E-11 | 2.283E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.005E-10 | 1.288E-07 | ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C9, XDH |
| BP | GO:0050896; response to stimulus | GO:0007197; adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway | 1.283E-10 | 1.470E-07 | CHRM1, CHRM2, CHRM3, CHRM5 |
| MF | GO:0060089; molecular transducer activity | GO:0016907; G-protein coupled acetylcholine receptor activity | 1.283E-10 | 1.470E-07 | CHRM1, CHRM2, CHRM3, CHRM5 |
| BP | GO:0050896; response to stimulus | GO:0007207; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway | 3.841E-10 | 3.983E-07 | CHRM1, CHRM2, CHRM3, CHRM5 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 8.602E-10 | 7.492E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.425E-09 | 1.821E-06 | AR, BLM, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESRRA, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.255E-08 | 7.589E-06 | CYP1A2, CYP2A6, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.751E-08 | 1.003E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C9, NOX4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.352E-07 | 1.067E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0023052; signaling | GO:0007271; synaptic transmission, cholinergic | 4.337E-07 | 1.782E-04 | CHRM1, CHRM2, CHRM3, CHRM5 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 5.861E-07 | 2.363E-04 | AR, CA2, CA9, CASP1, CYP1A1, CYP1A2, ESRRA, FLT3, HSD17B2, TP53, TYR |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.132E-06 | 4.179E-04 | CYP1A1, CYP2A6, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.946E-27 | 8.592E-23 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 7.853E-06 | 2.311E-03 | CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0009719; response to endogenous stimulus | 1.188E-05 | 3.316E-03 | AKR1B1, AR, BLM, CA2, CA9, CASP7, CYP1A2, ESRRA, FLT3, NOX4, TP53 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.526E-05 | 4.100E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.544E-05 | 4.100E-03 | AR, BLM, CASP7, CYP1A1, CYP1B1, FLT3, NOX4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.590E-05 | 4.171E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.025E-05 | 5.188E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.025E-05 | 5.188E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0008210; estrogen metabolic process | 2.311E-05 | 5.718E-03 | CYP1B1, HSD17B1, HSD17B2 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 2.882E-05 | 6.820E-03 | CASP1, CYP1A1, HIF1A, LMNA, NOX4, TP53 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.175E-05 | 7.054E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.175E-05 | 7.054E-03 | CYP1A2, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0004435; phosphatidylinositol phospholipase C activity | 3.323E-05 | 7.310E-03 | CHRM1, CHRM3, CHRM5 |
| BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 3.682E-05 | 7.933E-03 | AHR, AKR1B1, CA3, CYP1A1, CYP1B1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 4.448E-05 | 9.403E-03 | CYP1B1, HIF1A, NOX4, TP53, XDH |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.115E-20 | 2.303E-16 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.908E-19 | 1.702E-15 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.432E-26 | 2.359E-24 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 9.010E-08 | 2.573E-06 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.827E-08 | 1.371E-06 | CYP2C9; CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.923E-07 | 3.730E-06 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 6.147E-07 | 8.518E-06 | CYP2C9; CYP2A6; CYP1A2; CYP1A1; CYP1B1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 5.096E-07 | 8.239E-06 | CYP2C9; CYP1A2; ALOX15; CYP2C19 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.289E-05 | 1.328E-04 | CYP2C9; CYP2A6; HSD17B1; ALOX5; HSD17B2; CYP1A2; ALOX15; CYP1A1; AKR1B1; CYP2C19; TYR; XDH |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.134E-05 | 1.328E-04 | CYP2C9; ALOX5; ALOX15; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.369E-05 | 1.328E-04 | CYP2C9; CYP2A6; CYP1A2; CYP1A1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.737E-05 | 1.532E-04 | CYP2C9; CYP2A6; CYP1A2; CYP2C19 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.124E-04 | 8.059E-04 | CHRM2; CHRM3; CHRM1; CHRM5 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.163E-04 | 8.059E-04 | CYP2C9; ALOX5; ALOX15; CYP2C19 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 9.921E-05 | 8.020E-04 | CYP1A2; CYP1A1; CYP1B1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.061E-07 | 2.573E-06 | CYP2A6; CYP1A2; XDH |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 7.088E-04 | 4.297E-03 | CHRM2; CHRM3; CHRM1; CHRM5 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.611E-04 | 2.982E-03 | FLT3; TP53; HIF1A |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.912E-03 | 9.760E-03 | AR; FLT3; DAPK1; HIF1A; TP53 |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 1.347E-03 | 7.258E-03 | CHRM2; CHRM3; CHRM1; CHRM5 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 3.434E-03 | 1.666E-02 | CHRM2; CHRM3; CHRM1; CHRM5 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.842E-03 | 1.694E-02 | CASP7; LMNA; TP53 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.839E-03 | 1.694E-02 | DAPK1; TP53 |
| hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 1.206E-02 | 4.140E-02 | CHRM3; CA2 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 6.815E-03 | 2.542E-02 | CASP7; CASP1 |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 5.885E-03 | 2.283E-02 | CASP1; TP53 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.115E-02 | 4.005E-02 | CA2; ABCG2 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 4.811E-03 | 1.944E-02 | CYP2A6; XDH |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.238E-02 | 4.140E-02 | CASP7; CASP1 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 4.410E-03 | 1.860E-02 | ABCC1; ABCG2 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.215E-03 | 6.934E-03 | CA2; CA4 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; TYR; CASP1; AKR1B1; ESRRA |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| NA: NA | Addiction | NA | CHRM2 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain diseases | G00-G99 | CHRM5 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; FLT3; CA9 |
| NA: NA | Spasms | NA | CHRM3 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; CHRM3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | CHRM5; CHRM1; CHRM1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | CHRM5; CHRM1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Sjogren's syndrome | M35.0 | CHRM3 |
| NA: NA | Schizoaffective disorders | NA | CHRM1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1; CHRM3; CHRM1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; ABCC1; ABCC1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | CHRM5 |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Visceral spasms | R25.2 | CHRM1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5; CHRM3 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CHRM1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| C00-D49: Neoplasms | Melanoma | C43 | TYR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| G00-G99: Diseases of the nervous system G00-G99 | Central and peripheral nervous diseases | G96.9 | CHRM5 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | CHRM2 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | CHRM5; CHRM3; CHRM1; CHRM2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; HIF1A; TP53; CA1; FLT3; FLT3; CA9 |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| J00-J99: Diseases of the respiratory system | Obstructive lung diseases | J40-J44, J47 | CHRM3 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; CHRM5; CHRM3; CHRM1 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | CHRM5; CHRM1 |
| K00-K95: Diseases of the digestive system | Stomach ulcer | K25-K27 | CHRM5; CHRM1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; ESRRA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | CHRM1 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| K00-K95: Diseases of the digestive system | Colitis | K50-K52 | CHRM5 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; CHRM2 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3 |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | CHRM1; CHRM2 |
| N00-N99: Diseases of the genitourinary system | Overactive bladder | N32.81 | CHRM3 |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | CHRM3; CHRM1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnosing bronchial hyperreactivity | W88 | CHRM3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5 |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; CHRM2 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; FLT3; FLT3; CA9 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; CHRM2; ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | CHRM5 |
| NA: NA | Dystonia | NA | CHRM1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
| NA: NA | Extrapyramidal disorders secondary to neuroleptic drug therapy | NA | CHRM1 |
| NA: NA | Excessive sweating | NA | CHRM1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR |
| NA: NA | Abdominal stomach pain | NA | CHRM1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| NA: NA | GIST | NA | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| NA: NA | Functional bowel syndrome | NA | CHRM1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | CHRM1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Postoperative nausea and vomiting | R11 | CHRM3 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | CHRM1; CHRM1; CHRM2 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Stabilize muscle contractions | M00-M99 | CHRM2 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
| NA: NA | Male hypogonadism | NA | AR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | CHRM3; CHRM1; CHRM2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | CHRM5; ESRRA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Amnesia | F04 | CHRM5 |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; ABCC1; ESRRA |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| NA: NA | HIV infections | NA | AHR |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Seborrhea | L21 | CHRM3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CHRM5; CHRM1; CHRM1; CHRM1; ESRRA |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |